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In this mini-review, we summarize recent discoveries and present new hypotheses
on the role of cannabinoids in controlling trigeminal nociceptive system underlying
migraine pain. Individual sections of this review cover key aspects of this topic, such
as: (i) the current knowledge on the endocannabinoid system (ECS) with emphasis on
expression of its components in migraine related structures; (ii) distinguishing peripheral
from central site of action of cannabinoids, (iii) proposed mechanisms of migraine pain
and control of nociceptive traffic by cannabinoids at the level of meninges and in
brainstem, (iv) therapeutic targeting in migraine of monoacylglycerol lipase and fatty
acid amide hydrolase, enzymes which control the level of endocannabinoids; (v) dual
(possibly opposing) actions of cannabinoids via anti-nociceptive CB1 and CB2 and
pro-nociceptive TRPV1 receptors. We explore the cannabinoid-mediated mechanisms
in the frame of the Clinical Endocannabinoid Deficiency (CECD) hypothesis, which
implies reduced tone of endocannabinoids in migraine patients. We further discuss
the control of cortical excitability by cannabinoids via inhibition of cortical spreading
depression (CSD) underlying the migraine aura. Finally, we present our view on
perspectives of Cannabis-derived (extracted or synthetized marijuana components) or
novel endocannabinoid therapeutics in migraine treatment.
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INTRODUCTION
Migraine is a debilitating disorder most commonly characterized by a unilateral hemicranial
pulsating headache often accompanied by a great variety of other symptoms such as sensory
disturbances and nausea (Pavlovic et al., 2014; Russo, 2016). The full list of migraine criteria
is provided in the latest version of Headache Classification (ICHD-3 beta, 2013). Due to its
high prevalence and disruptive nature, the mechanisms contributing to migraine headache have
been intensely studied over many decades but remain debatable. The current consensus states
that migraine pain is caused by lowering of the threshold of nociceptive signal processing in
response to release of pro-inflammatory agents. Migraine attack’s initiation has been linked to
both environmental and hormonal triggers (Pavlovic et al., 2014), which lead to pathophysiological
changes due to a sterile neurogenic inflammation in meninges and activation of trigeminal sensory
nerves (Pietrobon and Moskowitz, 2013; Gouveia-Figueira et al., 2017).
The multifaceted nature of migraine makes it difficult to define the exact criteria for clinical
assessment, and may underlie the vast variability in the ways in which migraine patients
respond to existing modes of treatment. Additionally, many of the anti-migraine therapies carry
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adverse effects, a challenge which has caused discontinuation
of research and development of potential anti-migraine drugs
(Russo, 2015). For these reasons, introduction of new, more
inclusive and effective modes of therapy is urgently needed.
Different parts of Cannabis sativa plant have been utilized
for centuries in treatment of multitude of health conditions,
and consumption of this plant is often associated with
psychotropic effects such as mood fluctuations, intoxication,
euphoria, increased heart rate, physical dependence upon
long-term use, and cognitive impairment (Niyuhire et al.,
2007). Regarding migraine pathology, the vital characteristics
justifying the proposed use of medical cannabis include
anticonvulsive (Rosenberg et al., 2015), analgesic, antiemetic
(Parker et al., 2011), and anti-inflammatory effects (Nagarkatti
et al., 2009). Mainly due to their potent analgesic action,
marijuana-derived exogenous cannabinoids are currently being
used for symptomatic and prophylactic treatment in many
pain conditions (Oláh et al., 2017), including migraine-
associated pain (Chakrabarti et al., 2015). The use of exogenous
cannabinoids has been greatly debated as a mode of therapy
during past years, but the recent changes in legislation have
facilitated their use in several countries. Following the push
by the public for increasing cannabinoid availability, the
demand for research on cannabinoid substances has also
escalated.
This review aims to take a look at the recent publications
on the effectiveness and safety of cannabinoid-based migraine
treatment, as well as studies of the mechanisms underlying
therapeutic effects of these compounds. Based on our experience
in experimental studies of migraine, we discuss our own and
other available data on the potential applications of cannabinoid




Endocannabinoid system (ECS) is a comprehensive signaling
system present in virtually every cell type and playing a critical
role in maintaining body homoeostasis (Aizpurua-Olaizola
et al., 2017). ECS’ numerous components include the enzymes
responsible for synthesis of endocannabinoids (eCBs), specific
receptors of eCBs, and the post-activity neutralizing pathways
(Marco et al., 2012). Here we provide only a short overview of
this complex system related to discussion of migraine pathology.
To date, several major and many less explored components
of the ECS have been identified (Chakrabarti et al., 2015).
The most prevalent eCBs are 2-arachidonoylglycerol (2-AG)
and arachidonoylethanolamine (anandamide, AEA) (Figure 1).
Overall, 2-AG is considered the primary signaling molecule and is
abundantly expressed throughout the brain (Sugiura et al., 2002).
The action of eCBs is mimicked by the main pharmacological
components of marijuana, namely phytocannabinoids (pCBs),
including the psychotropic 19-tetrahydrocannabinol (THC) and
the non-psychotropic cannabidiol (CBD) (Oláh et al., 2017;
Figure 1).
The ECS signals are relayed primarily by two receptors: type 1
cannabinoid receptor (CB1), which is one of the most abundant
G-protein coupled receptor in the brain (Smith et al., 2017),
and type 2 cannabinoid receptor (CB2), which is functionally
related to CB1 but is expressed primarily in peripheral tissues
(Chakrabarti et al., 2015). Both CB1 and CB2 are natively
activated by eCBs 2-AG and AEA, but they also respond to
binding of pCBs. Thus, THC is thought to act primarily via its
potent activation of CB1 and CB2. The mechanism of action is
less clear for CBD, which has been reported to affect more than
65 discrete molecular targets and to have varied effects outside of
ECS (Bih et al., 2015).
One important issue remaining unsolved is how exactly eCBs
are released from cells. The traditional dogma states that bioactive
eCBs, unlike other neurotransmitters such as acetylcholine and
dopamine, are produced “on-demand” (Marsicano et al., 2003).
An alternative view suggests that eCBs may be pre-synthesized
and stored, much like neurotransmitters (Maccarrone et al., 2010;
Fonseca et al., 2013; Chakrabarti et al., 2015).
Endocannabinoid system is active in stress-responsive parts
of central and peripheral nervous system, functioning to reduce
pain and to alleviate neurodegenerative and inflammatory
damage (Preedy, 2017; Smith et al., 2017). Short-term effects
induced by eCBs have been shown to involve plastic changes
in many brain areas affecting pain sensation (Oláh et al., 2017).
All these mechanisms are linked, directly or indirectly, to the
migraine pathology.
MAPPING ECS EFFECTS IN MIGRAINE
MODELS – CENTRAL VS. PERIPHERAL
The importance of the trigeminovascular system (TGVS) in
migraine pathophysiology is widely recognized by experts in
the field. During a migraine attack, prolonged activation of the
TGVS – comprising meningeal trigeminal nerves and vessels
along with dural mast cells (MC) (Figure 1) — ultimately causes
sensitization of higher order neurons in the central nervous
system (CNS), leading to the persistent nociceptive signaling
(Burstein et al., 2015). Furthermore, the resulting sensitization
has been found to stimulate TGVS activity, creating a positive
feedback loop (Eroli et al., 2017). The main migraine mediator
associated with the TGVS system is the neuropeptide calcitonin
gene-related peptide (CGRP), which promotes vasodilation and
contributes to the sterile meningeal inflammation associated with
sensitization of nociceptive pathway (Giniatullin et al., 2008;
Villalón and Olesen, 2009; Pietrobon and Moskowitz, 2013;
Dux et al., 2016; Figure 1). All three key meningeal structures
(nerves, vessels and MC) can act as targets for the action of
pCBs or eCBs. Several papers from P. Goadsby lab have shown
that CGRP-induced dilation of dural blood vessels and neuronal
pro-nociceptive activity could be reduced by AEA (Akerman
et al., 2003, 2007). MC, populating the TGVS in large quantities
and responding to CGRP with degranulation (Figure 1), likely
play a triggering role in migraine (Levy, 2010; Kilinc et al.,
2017). In particular serotonin, a major component of mast cell
granules, is able to produce a robust activation of trigeminal
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FIGURE 1 | Potential targets for the anti-nociceptive action of phyto-cannabinoids (marijuana compounds) and eCBs in migraine pain. Migraine-associated pain
(pain propagating pathways are marked in brown) is generated in the TGVS comprising meningeal mast cells (MC), dural vessels and nociceptive trigeminal nerve
fibers. Activation of pro-nociceptive TRPV1 receptors in sensory neurons which cell bodies are located in the trigeminal ganglion (TG) surrounded by satellite glial
cells (SGC), results in release of the migraine mediator CGRP which can degranulate MC, provide a strong vasodilatory effect and target T-cells (TC). Degranulation
of MC is associated with release of multiple pro-inflammatory compounds (5-HT, histamine, cytokines) supporting local neuroinflammation and sensitization of
nociceptive fibers. Sensitized nerve fibers, via activation of certain subtypes of sodium channels (Nav), generate nociceptive firing (nociceptive spikes) propagated to
the brainstem and, later, to the higher pain centers where this nociceptive traffic is perceived as migraine pain. eCBs and exocannabinoids (marked in green)
including anandamide (AEA) and 2-arachidonoylglycerol (2-AG) as well as their exogenous counterparts THC and CBD, respectively, are promising agents to provide
the anti-nociception in migraine. The anti-nociceptive effect of eCBs depends on their local concentrations, determined by the balance between the synthesis and
degradation as well as availability and subtypes of their target receptors. The degradation of 2-AG is controlled by MAGL whereas hydrolysis of AEA is determined by
the activity of FAAH. As some eCBs, such as AEA, can also activate TRPV1 receptors, migraine-associated pain is affected by a delicate balance between
anti-nociceptive effects of CBs on specific cannabinoid receptors and pro-nociceptive effects on TRPV1 receptors. At peripheral site in meninges, CB1 receptors
expressed in peripheral trigeminal nerve endings can contribute to anti-nociception by reducing probability of spike generation and reducing release of CGRP.
Cannabinoid receptor type 1 (CB1) in the CNS is mainly expressed in neurons with predominant presynaptic location providing the inhibitory action of glutamate
release in the brainstem. CB1 subtype is also expressed in astrocytes (Metna-Laurent and Marsicano, 2015). Cannabinoid receptor type 2 (CB2) and GPR55 are
primarily expressed in cells of immune origin such as peripheral MC or T-cells as well as in microglial cells in the brain. Recent data also suggest heteromerization of
CB1 and CB2 receptors in activated microglia. Notably, microglia are much more efficient than astrocytes and neurons (Walter et al., 2003) in producing the major
eCB 2-AG which, in a paracrine way, can control neurons and, in autocrine manner, activate microglia.
afferents in meninges (Kilinc et al., 2017; Figure 1). Notably,
eCB operating via CB1 receptors can stabilize MC (Sugawara
et al., 2012) and this effect also contributes to the anti-migraine
action of these compounds. However, other data suggest a role
for CB2 and the orphan receptor GPR55 in the stabilizing action
of cannabinoids on mast cell HMC-1 line (Cantarella et al., 2011).
It is yet to be studied using migraine models, but similar mast cell
stabilizing effect in meninges could potentially contribute to the
anti-migraine action of cannabinoids (Figure 1).
Cannabinoid effects on the CNS are mediated primarily
by inhibitory CB1 receptors, located throughout CNS as well
as in afferent neurons (Marco et al., 2012). Both within
CNS and peripherally, eCBs act as retrograde messengers or
synaptic modulators for their respective target cells (Gabral
et al., 2015). Thus, one of the main functions of the eCB
2-AG, degraded by the enzyme monoacylglycerol lipase (MAGL,
Aaltonen et al., 2016), is to serve as a mediator of retrograde
signaling to downregulate neurotransmitter release (Smith et al.,
2017). Unlike the selective presynaptic inhibitory effect of
adenosine on excitatory glutamatergic terminals (Safiulina et al.,
2005), activation of CB1 receptor by eCB inhibits the release
from presynaptic terminals of both inhibitory and excitatory
neurotransmitters (Gabrielli et al., 2015; Iseger and Bossong,
2015).
CB2 receptor, being, like CB1 receptor, highly sensitive to
2-AG, possesses an individual set of expression patterns and
characteristic functions. Thus, CB2 expression is higher in
peripheral organs than in the CNS and is mostly restricted to the
immune system cells including B and T lymphocytes (Figure 1).
Endocannabinoid system contributes to both innate and adaptive
immune responses, functioning as a preventative force against
the onset of pro-inflammatory responses (Nagarkatti et al., 2009;
Oláh et al., 2017). CB2 receptors are primarily responsible for
exerting immunosuppressive effects in the periphery. During
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an inflammatory reaction, which is expected in most severe or
chronic forms of migraine, more of CB2 receptors are made
available for activation (Gabral et al., 2015). In our recent study,
familial migraine was found to be associated with enhanced
concentrations of key inflammatory cytokines detected in blood
(Khaiboullina et al., 2017). Thus, cannabinoids may act by
correcting the dysregulation of cytokine production (Nagarkatti
et al., 2009). Taken together, these studies suggest that the
less explored CB2 receptors possessing the anti-inflammatory
potential (Gabral et al., 2015) represent a promising target to
counteract migraine (Scherma et al., 2016).
Besides their independent functions, CB1 and CB2 receptors
have been shown to work together by forming hetero-receptor
complexes (Callen et al., 2012). This type of receptor-receptor
interaction has been shown recently for brain-residing immune
cells such as microglia. Thus, it has been recently shown that,
alongside CB2 receptors, the CB1-CB2 heteroreceptor complexes
are expressed in microglia (Smith et al., 2017; Navarro et al.,
2018; Figure 1). Microglia could play a part in the pathogenesis
of migraine with aura, since the cortical spreading depression
(CSD) associated with this type of migraine effectively activates
microglia (Shibata and Suzuki, 2017). CSD also releases ATP
(Karatas et al., 2013), which is a major driver of microglia,
promoting release of the eCB 2-AG (Walter et al., 2003). Notably,
the ability of microglia to secrete 2-AG is about 20-times higher
than that of astrocytes and neurons (Walter et al., 2003). In
view of the recent data, this link appears to be even more
intriguing as microglia are essential for initiation of CSD (Pusic
et al., 2014). Interestingly, this positive feedback loop could
be disrupted by agonists of CB1 (but not of CB2 receptors),
which block CSD (Kazemi et al., 2012). Consistent with growing
interest to the medications targeting receptor heteromers, a
study using the bivalent CB1 antagonist specifically affecting
dimerized CB1 receptors, showed pain-alleviating effects (Zhang
et al., 2010). Overall, di- and oligomerization of GPCRs
within CNS represent an attractive therapeutic target in pain
conditions (Borroto-Escuela et al., 2013; Fuxe and Borroto-
Escuela, 2015).
In peripheral migraine mechanisms, activation of TRPV1
receptor, a non-selective cation channel expressed in trigeminal
nociceptors, leads to massive CGRP release (Kageneck et al.,
2014; Figure 1). Our and other studies indicate an important
contribution of TRPV1 receptors to migraine pathology
(Zakharov et al., 2015; Dux et al., 2016). Stimulation of dural
sensory nerves by capsaicin was found to cause vasodilation
modulated by CGRP via TRPV1 receptor (Dux et al., 2016).
As the TRPV1 channels can also bind eCB AEA (Chakrabarti
et al., 2015), this may result in unwanted pro-nociceptive
action of cannabinoids, causing neuroinflammation in
meninges. This complexity may explain why increased
doses of cannabinoids diminished their analgesic effect
(Kandasamy et al., 2018). It further creates an incentive for
development of new synthetic CBs with minimal activity on
TRPV1 receptors, or specific MAGL inhibitors, which, apart
from triggering the accumulation of anti-nociceptive 2-AG,
can decrease the level of the pro-nociceptive arachidonic
acid (AA) and reduce pain (Aaltonen et al., 2016). MAGL
inhibitors may also reduce the pro-nociceptive downstream
products of AA such as endovanilloids, agonists of TRPV1
receptors (Hwang et al., 2000). Interestingly, the inhibition
of fatty acid amide hydrolase (FAAH) degrading AEA




Endocannabinoid system’s role in homeostatic upkeep highlights
the importance of this system in maintaining overall health.
Disruptions in supply or functionality of eCB ligands have
been connected to numerous mental state disturbances and,
particularly, to migraine. Migraine, along with comorbid
conditions such as fibromyalgia and irritable bowel syndrome,
share symptomatic commonalities of hyperalgesia as well
as treatment resistance, likely stemming from common
pathophysiological phenomenon: CECD. The CECD hypothesis
suggests a correlation between deficient levels of eCB and pain
(Russo, 2016).
Since the initial proposal of the CEDC in 2001, the
importance of maintaining regular eCB levels was shown in
a study comparing CB1- and CB2-KO mice that experienced
inflammation, to mice lacking FAAH (and thus having elevated
AEA) with reduced inflammation responses (Oláh et al., 2017).
The lowered inhibitory activity of eCS in migraine, possibly
due to reduced CB1 and CB2 receptor expression, serves as
an assertion for the compensatory therapy with exogenous
cannabinoids. According to the CECD hypothesis, treatment
of migraine using exogenous cannabinoids could be achieved
with low doses due to predisposition for elevated neuronal
excitability. The CECD-causing deficiencies can appear for
congenital reasons, or can be acquired.
PRO AND CONTRA OF CANNABINOIDS
IN MIGRAINE TREATMENT
There is a long history of using cannabinoids for effective
treatment of pain conditions. Due to their long-standing
status of out-lawed substances (Baron, 2015), it is worth
taking a look at the arguments still standing in the way of
legalization. Overall, targeting ECS with peripherally acting
drugs is a promising strategy for development of safe migraine
treatments. However, there are still many insufficiently explored
issues that may be detrimental for this seemingly harmless
treatment.
Regularly experiencing chronic migraine pain can have
adverse impacts on social relationships and job status which can
lead into psychological distress (Ramsden et al., 2015). As it
stands, the first ‘pro’ is that the treatment with pCB can acutely
alleviate the resulting stress, in addition to tackling the initial
cause by pain reduction.
In a study of the cannabis use for self-medication in Germany,
Austria and Switzerland, 10.2% of patients reported using it
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for migraine headache symptoms (Kandasamy et al., 2018).
Another group found that the self-treatment outcome was highly
variable, with low doses tending to alleviate migraine while
higher doses even triggering headaches (Lu and Anderson, 2017).
These findings call for creating a highly specific prescription
for individual patients, which would be required for safe and
successful treatment plan.
One of the main problems arising from the long-term usage
of cannabis is the physical reliance on the pCBs, mainly THC.
Moreover, there is evidence that patients can develop tolerance
for pCBs (Kandasamy et al., 2018). Carelessly establishing a
reliance on any form of medication may carry more ill effects on
the patient’s mentality, and may even lead to weakening or loss of
pain relief.
A crucial point when considering cannabinoid treatment
is that smoking marijuana is the most common method of
pCB self-administration. When self-administering pCBs via
smoking, the relief seekers often use marijuana mixed with
tobacco leaves. In view of the recently established crosstalk
between nicotinic cholinergic and ECS (Scherma et al.,
2016), the nicotinic cholinergic system has been proposed
as a molecular target for treating cannabis dependence
(Scherma et al., 2016). Particularly interesting is the ability
of the endogenous nicotinic antagonist kynurenic acid to
counteract the addictive effects of CBs (Justinova et al.,
2013). Notably, new derivatives of kynurenic acid were
suggested recently as promising medicines for migraine
(Greco et al., 2017) opening a new perspective for combined
CB+antinicotinic therapy of this disorder. Interestingly, the
main migraine mediator CGRP can reduce the activity of
nicotinic receptors (Giniatullin et al., 1999), suggesting that
the migraines associated with enhanced level of endogenous
CGRP are ‘pre-conditioned’ to respond better to CB
treatments.
Cannabidiol (CBD), the second most prevalent pCB,
should also be explored in relation to migraine treatment.
Unlike THC with its characteristic CB1 receptor affinity,
CBD does not have intoxicating and psychoactive effects
linked with CB1 receptor activation. Yet, CBD possesses
anxiolytic (anxiety-reducing) and antipsychotic properties
that have been suggested to be inflicted via interactions
with TRPV1 and non-endocannabinoid GPR55 receptor (Bih
et al., 2015). Recently, the US Food and Drug Administration
(FDA) accepted an application for Epidiolex R© (active agent
CBD) in treatment of seizures prominent in Lennox-Gastaut
syndrome (LGS) and Dravet syndrome (GW Pharmaceuticals,
2017). This stands as an important milestone paving the
way for possible repurposing of this CBD-based drug for
treating migraine, as well as other related neurological
conditions.
CONCLUSION
In summary, cannabinoids – due to their anticonvulsive,
analgesic, antiemetic, and anti-inflammatory effects – present
a promising class of compounds for both acute and
prophylactic treatment of migraine pain. In view of the
rapidly unfolding changes in the legal status of cannabis,
research on (endo)cannabinoids has become pertinent once
again. Formal approval of a cannabinoid-based drug for other
pathologies opens a possibility for repurposing these agents
also to treat migraine. The abundance of CB1 receptors in
the brain makes them an attractive target for treatment of
migraine via blocking not only peripheral but also the central
nociceptive traffic and reducing the pathologically enhanced
cortical excitability predisposing to CSD. CB2 receptors in
immune cells can be targeted to reduce the inflammatory
component associated with severe forms of migraine. Exogenous
compounds lacking the unwanted peripheral pro-nociceptive
component or eCBs generated via inhibited degradation
pathways and combined with other supportive agents are
most desirable for this aim. Moreover, primary stratification
of patients to identify and predict the effectiveness of
cannabinoid treatment can greatly improve the efficiency of this
approach.
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